Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Blueprint Medicines Corp (BPMC)
Blueprint Medicines Corp (BPMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,379,920
  • Shares Outstanding, K 60,790
  • Annual Sales, $ 204,040 K
  • Annual Income, $ -557,520 K
  • 60-Month Beta 0.68
  • Price/Sales 21.47
  • Price/Cash Flow N/A
  • Price/Book 21.62
Trade BPMC with:

Options Overview Details

View History
  • Implied Volatility 42.42% ( +1.50%)
  • Historical Volatility 79.65%
  • IV Percentile 11%
  • IV Rank 24.88%
  • IV High 67.57% on 12/30/22
  • IV Low 34.09% on 11/20/23
  • Put/Call Vol Ratio 56.07
  • Today's Volume 799
  • Volume Avg (30-Day) 286
  • Put/Call OI Ratio 1.68
  • Today's Open Interest 16,863
  • Open Int (30-Day) 16,595

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -2.02
  • Number of Estimates 11
  • High Estimate -1.84
  • Low Estimate -2.26
  • Prior Year -2.65
  • Growth Rate Est. (year over year) +23.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.74 +28.15%
on 11/13/23
74.00 -1.73%
on 12/04/23
+12.95 (+21.67%)
since 11/03/23
3-Month
43.89 +65.69%
on 10/25/23
74.00 -1.73%
on 12/04/23
+22.08 (+43.60%)
since 09/01/23
52-Week
37.82 +92.28%
on 02/24/23
74.00 -1.73%
on 12/04/23
+23.79 (+48.62%)
since 12/02/22

Most Recent Stories

More News
Why Blueprint Medicines Stock Soared Today

The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.

BPMC : 72.72 (+0.93%)
Blueprint Medicines: Q3 Earnings Snapshot

Blueprint Medicines: Q3 Earnings Snapshot

BPMC : 72.72 (+0.93%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint...

BPMC : 72.72 (+0.93%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint...

BPMC : 72.72 (+0.93%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint...

BPMC : 72.72 (+0.93%)
Why Shares of Blueprint Medicines Are Falling Wednesday

The company had generally improved earnings.

BPMC : 72.72 (+0.93%)
Blueprint Medicines: Q2 Earnings Snapshot

Blueprint Medicines: Q2 Earnings Snapshot

BPMC : 72.72 (+0.93%)
Blueprint Medicines Reports Second Quarter 2023 Results

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended...

BPMC : 72.72 (+0.93%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint...

BPMC : 72.72 (+0.93%)
What Will AbbVie Buy Next?

Two mid-cap drugmakers stand out as logical targets for AbbVie.

AGN.AX : 0.480 (unch)
ABBV : 144.15 (+0.52%)
BPMC : 72.72 (+0.93%)
KRYS : 104.92 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

See More

Key Turning Points

3rd Resistance Point 77.96
2nd Resistance Point 75.98
1st Resistance Point 74.35
Last Price 72.72
1st Support Level 70.74
2nd Support Level 68.76
3rd Support Level 67.13

See More

52-Week High 74.00
Last Price 72.72
Fibonacci 61.8% 60.18
Fibonacci 50% 55.91
Fibonacci 38.2% 51.64
52-Week Low 37.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar